Last reviewed · How we verify

Iopamidol 370 mgI/dL

Bracco Diagnostics, Inc · FDA-approved active Small molecule

Iopamidol 370 mgI/dL is a Non-ionic iodinated contrast medium Small molecule drug developed by Bracco Diagnostics, Inc. It is currently FDA-approved for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.

Iopamidol is a non-ionic iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.

Iopamidol is a non-ionic iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.

At a glance

Generic nameIopamidol 370 mgI/dL
SponsorBracco Diagnostics, Inc
Drug classNon-ionic iodinated contrast medium
ModalitySmall molecule
Therapeutic areaDiagnostic Imaging
PhaseFDA-approved

Mechanism of action

Iopamidol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. It distributes through the vascular system and extracellular space, allowing visualization of blood vessels, organs, and tissues during angiography, CT, and other imaging studies. The non-ionic formulation reduces osmolality and associated adverse effects compared to older ionic contrast agents.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Iopamidol 370 mgI/dL

What is Iopamidol 370 mgI/dL?

Iopamidol 370 mgI/dL is a Non-ionic iodinated contrast medium drug developed by Bracco Diagnostics, Inc, indicated for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.

How does Iopamidol 370 mgI/dL work?

Iopamidol is a non-ionic iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.

What is Iopamidol 370 mgI/dL used for?

Iopamidol 370 mgI/dL is indicated for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.

Who makes Iopamidol 370 mgI/dL?

Iopamidol 370 mgI/dL is developed and marketed by Bracco Diagnostics, Inc (see full Bracco Diagnostics, Inc pipeline at /company/bracco-diagnostics-inc).

What drug class is Iopamidol 370 mgI/dL in?

Iopamidol 370 mgI/dL belongs to the Non-ionic iodinated contrast medium class. See all Non-ionic iodinated contrast medium drugs at /class/non-ionic-iodinated-contrast-medium.

What development phase is Iopamidol 370 mgI/dL in?

Iopamidol 370 mgI/dL is FDA-approved (marketed).

What are the side effects of Iopamidol 370 mgI/dL?

Common side effects of Iopamidol 370 mgI/dL include Contrast-induced nephropathy, Allergic reaction, Nausea and vomiting, Flushing and warmth sensation, Hypersensitivity reactions.

Related